about
Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.Retinoblastoma: an overview.Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and ageSinonasal melanoma arising from conjunctival primary acquired melanosis.Retinoblastoma and hypochondroplasia: a case report of two germline mutations arising simultaneously.Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.Sonography of the eye.Current treatment and management of retinoblastoma.Retinoblastoma in the perinatal and neonatal child.Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience.Diagnostic Ophthalmic Ultrasound for Radiologists.Late Presentation of Retinoblastoma in a Teen with Aicardi Syndrome.Conjunctival Melanoma-Clinical Pearls Now, Hope for the Future.Neuro-ophthalmologic manifestations of cholangiocarcinoma: a case series.Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation.Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2.Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy.GPNMB expression in uveal melanoma: a potential for targeted therapy.A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma.Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists.Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.Re: "Retinoblastoma associated orbital cellulitis".Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort StudyProceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology ConferenceAdjuvant Ipilimumab in High-Risk Uveal MelanomaFamilial retinoblastoma: where and when?Orbital and optic chiasmal extension of uveal melanomaCurrent management of retinoblastomaGeographic disparities in diagnostic screening for metastatic uveal melanomaIntra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial?Choroidal and conjunctival metastases from renal cell carcinomaLeuprolide monotherapy for choroidal metastasis from prostate adenocarcinomaA choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanomaUtilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal MelanomaMetastatic Melanoma of the Optic Nerve SheathPazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trialPilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma
P50
Q33243831-ABFA71E7-40C7-4E72-AC2B-FA946A88A4F2Q33426914-1DEE36A2-6064-4250-832E-704D63C1CA00Q33839273-EBC5F31B-9141-47F6-935A-85575E10B48EQ34197461-01338039-0CBE-4A02-8943-1EA9095F966AQ34500975-82ACB1BA-3BBA-41D2-A843-17DCA0CAFC6BQ35109092-A6199674-5A26-49C8-913B-6C1FBEF0EE96Q36195239-B3262423-E1A5-4B79-8C7D-550554666726Q36383018-5F609828-4451-454C-93B8-70C37FB1E9D3Q36598150-9A79FE85-BDA3-4965-8B18-176DC0F6B5B9Q36996778-04B61BD6-B816-4B31-AC44-069716822370Q38012602-1249A662-25A9-431A-AD1A-398134743AF2Q38175837-7594B6A9-8467-4FD7-8EA8-52B6BF9C1AEFQ38553618-CC9C3FD0-B8C9-4565-BC1E-9501D4A430E5Q38847987-0AB71F7E-C6EA-4BB1-98D4-F7C0C7BD938EQ38957813-D1C8DF09-3A53-4B4E-A029-FDFED8A7117EQ39302541-9B9BE75F-E9E5-4B64-B23A-9F4C71E028B0Q39320044-11E46405-8D71-4A7C-930A-731D2E3663D5Q40261877-2DCC8872-E8F4-4CA4-9D6D-4F73AFB4A10EQ42135473-673FBE49-1840-4E97-80BE-B9597FB63544Q42655793-3A8B34E6-47C7-44CA-A425-71CBBD41CD0FQ43421516-A82C5521-941C-4376-AB08-D238FED64785Q45873438-6D6DA55A-1E08-457B-B921-9CF0F505FE88Q50658566-079ACD07-A7D3-4138-8929-25EA1F7A523AQ53161927-1DCD5233-21EA-4E2E-85A8-DD1534929062Q55668870-5B23D190-06DB-47B7-A171-F1D6EC860E6DQ58547944-B7E3CA05-51BC-4F32-8714-9CF6C98708B4Q64226587-551EA2B1-98AB-40EF-B621-82875FF56BA9Q64245594-3542F477-65DD-4EBD-A8D9-1BD71C98D146Q74827866-2E741FBC-B3EA-4125-BCE4-A80E7CE37C14Q80586657-C8AF14D5-34E2-413A-AE39-3D410E9DDD20Q81097177-BFD79AD2-BA3A-44F5-BBF9-CE3FEE02E275Q81101869-2E53A003-C681-4E57-83EA-0EC6798502F9Q82508214-31DAFC0F-8669-47BA-9513-B8F89F86B403Q84354494-0B0C2835-03D8-4AD2-B327-30B30B2221BDQ84958761-2398049B-CD3C-419D-BE5E-BDBC84AB545AQ86053475-B91FCA68-51A5-483B-B3C6-0FC801345943Q88663272-36D2BE32-E1BA-41BC-BAB7-44D5FCC1DD0EQ88798683-5A360782-6FEF-4C4B-B87A-AC0CBB9C12EAQ91590231-C2BF9ED3-1DFF-4EB6-9BED-0F73CCB88B54Q92940989-11372630-1DDF-4D41-A79F-B09EAAADB426
P50
description
researcher
@en
name
D S Gombos
@en
D S Gombos
@nl
type
label
D S Gombos
@en
D S Gombos
@nl
prefLabel
D S Gombos
@en
D S Gombos
@nl
P106
P31
P496
0000-0003-2867-6320